J 2013

Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries.

PAGANO, Livio, Oliver A. CORNELY, Alessandro BUSCA, Morena CAIRA, Simone CESARO et. al.

Basic information

Original name

Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries.

Authors

PAGANO, Livio (380 Italy), Oliver A. CORNELY (276 Germany), Alessandro BUSCA (380 Italy), Morena CAIRA (380 Italy), Simone CESARO (380 Italy), Cristiana GASBARRINO (380 Italy), Corrado GIRMENIA (380 Italy), Werner J. HEINZ (276 Germany), Raoul HERBRECHT (250 France), Cornelia LASS-FLÖRL (40 Austria), Annamaria NOSARI (380 Italy), Leonardo POTENZA (380 Italy), Zdeněk RÁČIL (203 Czech Republic, guarantor, belonging to the institution), Volker RICKERTS (276 Germany), Donald C. SHEPPARD (124 Canada), Arne SIMON (276 Germany), Andrew J. ULLMAN (276 Germany), Caterina Giovanna VALENTINI (380 Italy), Jörg Janne VEHRESCHILD (276 Germany), Anna CANDONI (380 Italy) and Maria J.G.T. VEHRESCHILD (276 Germany)

Edition

Haematologica, Pavia, ITALY, Ferrata Storti Foundation, 2013, 0390-6078

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Italy

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 5.868

RIV identification code

RIV/00216224:14740/13:00069044

Organization unit

Central European Institute of Technology

UT WoS

000328543400002

Keywords in English

posaconazole; lipid fomulations of amphotericin B; Mucormycosis; combination therapy; invasive fungal infections; hematological malignancies

Tags

Tags

International impact, Reviewed
Změněno: 28/4/2014 16:01, Olga Křížová

Abstract

V originále

Our case series may have been subject to selection bias, as only those patients who survived long enough to receive a combination therapy were included. However, since interventional trials on this question are unlikely to be performed any time soon, data from registries remain the only available source of structured information on the treatment of mucormycosis. In conclusion, our analysis suggests that a combined antifungal treatment with Lip-AmB+POS may be considered in patients with very aggressive forms of IM.